Phaseline

Companies › MacroGenics

MacroGenics: clinical trials, targets and expected readouts

5 active drug programs in 8 registered trials: 4 Phase 1, 4 Phase 2; Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lorigerlimab
Bispecific DART protein binding PD-1 and CTLA-4
PDCD1, CTLA4Phase 2Platinum-resistant Ovarian Cancer; Colorectal Cancer; Metastatic Cancer; Pancreatic AdenocarcinomaJul 2027
MGC028
anti-ADAM9 antibody-drug conjugate
ADAM9Phase 1Advanced Solid TumorsNov 2026
MGD024
CD123 x CD3 bispecific DART molecule
CD123, CD3Phase 1Leukemia, Acute MyeloidNov 2026
MGC030
Antibody-drug conjugate
–Phase 1Urothelial CancerSep 2028
vobramitamab tavatecan
anti-TROP2 antibody-drug conjugate with SN-38 payload
TROP2Phase 1Advanced Solid TumorOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06723236MGC028Phase 1Advanced Solid TumorsOncologyNov 2026
NCT05362773MGD024Phase 1Leukemia, Acute MyeloidOncologyNov 2026
NCT07071961LorigerlimabPhase 2Colorectal CancerOncologyMay 2027
NCT06730347LorigerlimabPhase 2Platinum-resistant Ovarian CancerOncologyJul 2027
NCT05475171LorigerlimabPhase 2Metastatic CancerOncologyJun 2028
NCT07822399MGC030Phase 1Urothelial CancerGastroenterologySep 2028
NCT06242470vobramitamab tavatecanPhase 1Advanced Solid TumorOncologyOct 2028
NCT07565155LorigerlimabPhase 2Pancreatic AdenocarcinomaOncologyJan 2032

From the company's SEC filings

Cash of $114m on 2026-06-30; operating cash outflow about $155m a year; runway about 9 months at that burn, to Mar 2027; 0 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TROP2 (1) ADAM9 (1) CD123 (1) CD3 (1) PDCD1 (1) CTLA4 (1)

Companies with the same targets

Akeso AstraZeneca Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech GSK Mabwell (Shanghai) Bioscience Bio-Thera Solutions Johnson & Johnson (Janssen) OncoC4

Companies built like this

TScan Therapeutics Tyra Biosciences Agenus Xencor Shanghai Juncell Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.